Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28M
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
18M
-
Shares change
-
+3.41M
-
Total reported value, excl. options
-
$180M
-
Value change
-
+$33.9M
-
Put/Call ratio
-
2.85
-
Number of buys
-
43
-
Number of sells
-
-43
-
Price
-
$10.01
Significant Holders of NextCure, Inc. - Common Stock (NXTC) as of Q1 2021
106 filings reported holding NXTC - NextCure, Inc. - Common Stock as of Q1 2021.
NextCure, Inc. - Common Stock (NXTC) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18M shares
of 28M outstanding shares and own 64.08% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (2.71M shares), Sofinnova Investments, Inc. (2.67M shares), BlackRock Inc. (2.16M shares), CITADEL ADVISORS LLC (1.06M shares), MORGAN STANLEY (978K shares), VANGUARD GROUP INC (844K shares), Canaan Partners X LLC (838K shares), HILLHOUSE CAPITAL ADVISORS, LTD. (564K shares), Ikarian Capital, LLC (454K shares), and Voya Investment Management LLC (449K shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.